Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) shares closed down 44% at $14.85 after its trial for Angelman syndrome failed to meet its primary endpoint, marking a clinical setback for the program.
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) Chief Legal Officer Scott Bizily executed a sequence of option exercises and subsequent sales involving 584 shares at prices between $6.49 and $14.
Senti Biosciences, Inc. (NASDAQ: SNTI) raised $2 million via senior secured convertible notes issued to NSG BioInnovation Fund and established a $2.5 million equity agreement with a Celadon affiliate contingent on its pending merger.
Summit Therapeutics Inc. (NASDAQ: SMMT) shares closed up 17% at $17.13 following partner Akeso's report that Chinese Phase 3 results for ivonescimab demonstrated improved survival compared to Merck's Keytruda in lung cancer patients.
American Outdoor Brands, Inc. (NASDAQ: AOUT) shares surged 25.47% to $12.56 in after-hours trading Thursday after the Missouri-based provider of outdoor products and accessories announced its first-quarter fiscal 2027 results, withEarnings Per Shareof $0.03 topping analysts' expectations by 112%. In the regular session, AOUT …
Immuron Limited (NASDAQ: IMRN) entered into an exclusive distribution agreement within the United States with Calmino Group AB for PROIBS, broadening its digestive wellness lineup alongside Travelan.
Clearmind Medicine Inc. (NASDAQ: CMND) entered a definitive agreement to acquire a 51% stake in EV wireless charging company Charging Robotics for $2.5 million plus a $1.5 million 4% loan.
Net appointed Cesar Herrera to itsBoard of Directorsand to its Audit and Compensation Committees, effective August 30, 2026, following the resignation of director Avi Liss.
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) received FDA approval for Zanvastro to treat Alexander disease in both children and adults.
Aethlon Medical, Inc. (NASDAQ: AEMD) secured a notice of allowance from the USPTO for a patent regarding technology for managing viral infections and their symptoms.